ProCE Banner Activity

CME

Emerging Strategies in Hemophilia: Restoring the Homeostatic Balance

Multimedia
Watch this on-demand webcast of a live CCO satellite symposium to learn more about recent advances, unmet clinical needs, and the future of hemophilia therapy.

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: September 26, 2022

Expiration: September 25, 2023

No longer available for credit.

Share

Faculty

Guy Young

Guy Young, MD

Director, Hemostasis and Thrombosis Center
Director, Clinical Coagulation Laboratory
Cancer and Blood Disorders Institute
Children's Hospital Los Angeles
Professor of Pediatrics
Division of Hematology/Oncology
Department of Pediatrics
University of Southern California Keck School of Medicine
Los Angeles, California

Glaivy Batsuli

Glaivy Batsuli, MD

Assistant Professor of Pediatrics
Pediatric Hematologist
Division of Pediatric Hematology and Oncology
Department of Pediatrics
Emory University
Pediatric Hematologist
Pediatric Hematology and Oncology
Aflac Cancer and Blood Disorders Center of Childrens Healthcare of Atlanta
Atlanta, Georgia

Allison Wheeler

Allison Wheeler, MD, MSCI

Associate Professor
Department of Pathology, Microbiology, and Immunology
Department of Pediatrics
Vanderbilt University Medical Center
Nashville, Tennessee

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Novo Nordisk Inc

Target Audience

This program is intended for hematologists and other healthcare professionals who care for patients with hemophilia A and B.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Describe the engineered mechanism by which new therapies for hemophilia A and B can restore hemostatic balance
  • Evaluate the available data for investigational hemophilia agents and their ability to improve patient outcomes without introducing new health risks
  • Identify patients with hemophilia A or B who may be eligible for enrollment on a clinical trial investigating agents that target anticoagulant pathways or next-generation bispecific antibodies
  • Integrate hemophilia therapies that aim to restore hemostatic balance into clinical practice as they become available

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Program Director Disclosure

Program Director

Guy Young, MD

Director, Hemostasis and Thrombosis Center
Director, Clinical Coagulation Laboratory
Cancer and Blood Disorders Institute
Children's Hospital Los Angeles
Professor of Pediatrics
Division of Hematology/Oncology
Department of Pediatrics
University of Southern California Keck School of Medicine
Los Angeles, California

Guy A. Young, MD: consultant/advisor/speaker: BioMarin, Genentech/Roche, Grifols, Novo Nordisk, Pfizer, Sanofi, Spark, Takeda.

Faculty Disclosure

Primary Author

Glaivy Batsuli, MD

Assistant Professor of Pediatrics
Pediatric Hematologist
Division of Pediatric Hematology and Oncology
Department of Pediatrics
Emory University
Pediatric Hematologist
Pediatric Hematology and Oncology
Aflac Cancer and Blood Disorders Center of Childrens Healthcare of Atlanta
Atlanta, Georgia

Glaivy Batsuli, MD: independent contractor: for Bio Products Laboratories, Kedrion

Allison Wheeler, MD, MSCI

Associate Professor
Department of Pathology, Microbiology, and Immunology
Department of Pediatrics
Vanderbilt University Medical Center
Nashville, Tennessee

Allison Wheeler, MD, MSCI: consultant/advisor/speaker: Bayer, Bioverativ, Novo Nordisk, Sanofi, Spark, Takeda.

Staff Disclosure

Staff

Nathan Beach, PhD

Editorial Contributor

Nathan Beach, PhD, has no relevant financial relationships to disclose.

Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant financial relationships to disclose.

Krista Marcello,

Associate Managing Editor

Krista Marcello has no relevant financial relationships to disclose.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant financial relationships to disclose.

Shara Pantry, PhD

Associate Scientific Director

Shara Pantry, PhD, has no relevant financial relationships to disclose.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant financial relationships to disclose.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from September 26, 2022, through September 25, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve the knowledge, competence, and performance of learners in using new and emerging therapeutic options for patients with hemophilia A and B.